UK Markets closed

Novo Nordisk A/S (NVO)

NYSE - NYSE Delayed price. Currency in USD
Add to watchlist
95.36-0.10 (-0.10%)
At close: 04:00PM EST
95.00 -0.36 (-0.38%)
After hours: 07:51PM EST
Full screen
Trade prices are not sourced from all markets
Previous close95.46
Bid94.70 x 900
Ask95.00 x 1100
Day's range95.12 - 96.89
52-week range66.59 - 117.35
Avg. volume1,245,366
Market cap217.381B
Beta (5Y monthly)0.26
PE ratio (TTM)31.41
Earnings dateN/A
Forward dividend & yield1.47 (1.39%)
Ex-dividend date16 Aug 2021
1y target estN/A
  • Globe Newswire

    Novo Nordisk A/S – Share repurchase programme

    Novo Nordisk A/S – Share repurchase programme Bagsværd, Denmark, 17 January 2022 – On 5 November 2021, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 20 billion to be executed during a 12-month period

  • Globe Newswire

    Novo Nordisk announces settlement of securities lawsuit in Denmark

    Bagsværd, Denmark, 14 January 2022 – Novo Nordisk today announced that the company has settled a securities lawsuit in Denmark filed in August 2019. The settlement contains no admission of liability, wrongdoing or responsibility by Novo Nordisk and no payment will be made by Novo Nordisk to the plaintiffs. The lawsuit was filed by a number of shareholders and alleged that Novo Nordisk had made misleading statements and did not make appropriate disclosures regarding its sales of insulin products

  • Globe Newswire

    Novo Nordisk announces supply challenges for Wegovy® in the US

    Bagsværd, Denmark, 17 December 2021 – Novo Nordisk today announced that a contract manufacturer filling syringes for Wegovy® pens for the US market has temporarily stopped deliveries and manufacturing following issues with Good Manufacturing Practices. As a consequence, Novo Nordisk does not expect to be able to meet demand in the US in the first half of 2022 and few new patients are expected to be able to initiate treatment. The priority for Novo Nordisk is patients who have already initiated t